Screener
Immunome IMNM EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Immunome’s reported figures.
Based on trailing twelve months.
The source filing: Immunome’s 10-Q, filed May 12, 2026. Open the filing →
- Filed
- May 12, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219425
FAQ
- What is Immunome's EBITDA margin?
- Immunome (IMNM) reported EBITDA margin of -5,886.7% in Q1 2026.
- How has Immunome's EBITDA margin changed year-over-year?
- Immunome's EBITDA margin decreased by 197.9% year-over-year, from -1,975.8% to -5,886.7%.
- What is the long-term trend for Immunome's EBITDA margin?
- Over 2 years (2023 to 2025), Immunome's EBITDA margin has grown at a 102.6% compound annual growth rate (CAGR), from -778.1% to -3,193.3%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about Immunome's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude